These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 38721669)
1. Functional exploration of copy number alterations in a Drosophila model of triple-negative breast cancer. Diaz JEL; Barcessat V; Bahamon C; Hecht C; Das TK; Cagan RL Dis Model Mech; 2024 Jul; 17(7):. PubMed ID: 38721669 [TBL] [Abstract][Full Text] [Related]
2. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035 [TBL] [Abstract][Full Text] [Related]
3. Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer. Johnson JP; Kumar P; Koulnis M; Patel M; Simin K Cancer Genomics Proteomics; 2014; 11(3):115-26. PubMed ID: 24969692 [TBL] [Abstract][Full Text] [Related]
4. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567 [TBL] [Abstract][Full Text] [Related]
5. Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer. Suelmann BBM; Rademaker A; van Dooijeweert C; van der Wall E; van Diest PJ; Moelans CB Cell Oncol (Dordr); 2022 Aug; 45(4):591-600. PubMed ID: 35792986 [TBL] [Abstract][Full Text] [Related]
6. Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. Silvestri M; Dugo M; Vismara M; De Cecco L; Lanzoni D; Vingiani A; Folli S; De Santis MC; de Braud F; Pruneri G; Di Cosimo S; Cappelletti V Sci Rep; 2022 Jan; 12(1):1470. PubMed ID: 35087134 [TBL] [Abstract][Full Text] [Related]
7. QNBC Is Associated with High Genomic Instability Characterized by Copy Number Alterations and miRNA Deregulation. Bhattarai S; Sugita BM; Bortoletto SM; Fonseca AS; Cavalli LR; Aneja R Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768979 [TBL] [Abstract][Full Text] [Related]
8. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells. Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350 [TBL] [Abstract][Full Text] [Related]
9. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer. Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117 [TBL] [Abstract][Full Text] [Related]
10. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer. Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349 [TBL] [Abstract][Full Text] [Related]
11. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients. Nagahashi M; Ling Y; Toshikawa C; Hayashida T; Kitagawa Y; Futamura M; Kuwayama T; Nakamura S; Yamauchi H; Yamauchi T; Kaneko K; Kanbayashi C; Sato N; Tsuchida J; Moro K; Nakajima M; Shimada Y; Ichikawa H; Lyle S; Miyoshi Y; Takabe K; Okuda S; Wakai T Breast Cancer; 2023 Jul; 30(4):584-595. PubMed ID: 36930419 [TBL] [Abstract][Full Text] [Related]
12. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564 [TBL] [Abstract][Full Text] [Related]
13. Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets. Wang X; Guda C Medicine (Baltimore); 2016 Jul; 95(30):e4321. PubMed ID: 27472710 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer. Li Z; Zhang X; Hou C; Zhou Y; Chen J; Cai H; Ye Y; Liu J; Huang N Int J Oncol; 2020 Feb; 56(2):522-530. PubMed ID: 31894314 [TBL] [Abstract][Full Text] [Related]
15. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Silva GO; He X; Parker JS; Gatza ML; Carey LA; Hou JP; Moulder SL; Marcom PK; Ma J; Rosen JM; Perou CM Breast Cancer Res Treat; 2015 Jul; 152(2):347-56. PubMed ID: 26109346 [TBL] [Abstract][Full Text] [Related]
16. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199 [TBL] [Abstract][Full Text] [Related]
17. Clonal fitness inferred from time-series modelling of single-cell cancer genomes. Salehi S; Kabeer F; Ceglia N; Andronescu M; Williams MJ; Campbell KR; Masud T; Wang B; Biele J; Brimhall J; Gee D; Lee H; Ting J; Zhang AW; Tran H; O'Flanagan C; Dorri F; Rusk N; de Algara TR; Lee SR; Cheng BYC; Eirew P; Kono T; Pham J; Grewal D; Lai D; Moore R; Mungall AJ; Marra MA; ; McPherson A; Bouchard-Côté A; Aparicio S; Shah SP Nature; 2021 Jul; 595(7868):585-590. PubMed ID: 34163070 [TBL] [Abstract][Full Text] [Related]
18. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881 [TBL] [Abstract][Full Text] [Related]
19. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570 [TBL] [Abstract][Full Text] [Related]
20. PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer. Zhuang F; Huang S; Liu L Int J Biochem Cell Biol; 2024 Jun; 171():106581. PubMed ID: 38642827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]